Microglia.ai
← All programs

Last reviewed: June 2, 2026

AbCellera

Trem2 Antibody

TargetTREM2
Modalitymonoclonal antibody
IndicationAlzheimer's disease
PhasePreclinical
PartnerNone

Notes

Preclinical stage TREM2 activating antibody utilizing AbCellera's discovery platform. Designed to modulate microglial activity for neurodegeneration.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 2, 2026